Concert Pharmaceuticals, Inc. and Celgene Corporation (CELG) Tie the Knot in a $300 Million Tech Deal
5/6/2013 7:10:24 AM
More...
|
Concert Pharmaceuticals, Inc. to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013
4/23/2013 6:52:38 AM
More...
|
Concert Pharmaceuticals, Inc. to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013
4/23/2013 6:17:15 AM
More...
|
Concert Pharmaceuticals, Inc., Jazz Pharmaceuticals plc (JAZZ) Strike $120 Million Deal for Narcolepsy
2/27/2013 7:31:38 AM
More...
|
Concert Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Health Care Conference on March 5, 2013
2/27/2013 6:41:03 AM
More...
|
Concert Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 CTP-499 Clinical Trial for the Treatment of Diabetic Kidney Disease
2/19/2013 9:26:44 AM
More...
|
Concert Pharmaceuticals, Inc. Announces Milestone Achievement in AVANIR Pharmaceuticals (AVNR) Collaboration
2/7/2013 9:57:16 AM
More...
|
Concert Pharmaceuticals, Inc. Presents Findings Demonstrating Enhanced Potency of CTP-221, a Deuterated S-Enantiomer of Lenalidomide
12/10/2012 10:02:19 AM
More...
|
Concert Pharmaceuticals, Inc. Presents Preclinical Results Demonstrating CTP-499, a Novel Treatment for Diabetic Kidney Disease, Ameliorated Renal Fibrosis and Inflammation In Vivo
11/2/2012 9:02:42 AM
More...
|
Concert Pharmaceuticals, Inc. Announces Issuance of U.S. Patent for Its Lead Drug Candidate CTP-499
10/22/2012 9:17:29 AM
More...
|
|